The Carlyle Group Inc. 13D and 13G filings for eFFECTOR Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-05-13 4:05 pm Sale | 2024-05-09 | 13D | eFFECTOR Therapeutics, Inc. EFTR | Carlyle Group Inc. CG | 193,195 4.100% | -1 (-0.00%) | Filing |
| 2023-08-18 4:16 pm Unchanged | 2023-08-08 | 13D | eFFECTOR Therapeutics, Inc. EFTR | Carlyle Group Inc. CG | 193,196 7.800% | 0 (Unchanged) | Filing |
| 2022-08-11 4:55 pm Purchase | 2022-08-01 | 13D | eFFECTOR Therapeutics, Inc. EFTR | Carlyle Group Inc. CG | 193,196 11.700% | 193,196 (New Position) | Filing |